TY - JOUR
T1 - Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
AU - Jabbour, Elias
AU - Kantarjian, Hagop
AU - O'Brien, Susan
AU - Rios, Mary Beth
AU - Abruzzo, Lynne
AU - Verstovsek, Srdan
AU - Garcia-Manero, Guillermo
AU - Cortes, Jorge
PY - 2006/1/15
Y1 - 2006/1/15
N2 - Sudden blastic transformation (SBT) has been reported in 0.5% to 2.5% of patients treated with interferon-α (IFN-α) during the first 3 years of therapy. Imatinib is now standard therapy for patients with chronic myeloid leukemia in chronic phase. We investigated the occurrence of SBT among patients treated with imatinib. Among 541 patients treated with imatinib in chronic phase, 23 developed blast phase, which was of sudden onset (ie, occurring in patients previously in complete cytogenetic remission) in 4 patients (17%; 0.7% of the total), 2 lymphoid and 2 myeloid. Patients with SBT were found to have low-risk features more often at the time of presentation and had achieved optimal response with imatinib. Three of the 4 patients underwent allogeneic stem cell transplantation and achieved a molecular remission. SBT is still a rare event, probably less common than that observed with IFN-α therapy. Continuous monitoring of patients treated with imatinib is mandatory.
AB - Sudden blastic transformation (SBT) has been reported in 0.5% to 2.5% of patients treated with interferon-α (IFN-α) during the first 3 years of therapy. Imatinib is now standard therapy for patients with chronic myeloid leukemia in chronic phase. We investigated the occurrence of SBT among patients treated with imatinib. Among 541 patients treated with imatinib in chronic phase, 23 developed blast phase, which was of sudden onset (ie, occurring in patients previously in complete cytogenetic remission) in 4 patients (17%; 0.7% of the total), 2 lymphoid and 2 myeloid. Patients with SBT were found to have low-risk features more often at the time of presentation and had achieved optimal response with imatinib. Three of the 4 patients underwent allogeneic stem cell transplantation and achieved a molecular remission. SBT is still a rare event, probably less common than that observed with IFN-α therapy. Continuous monitoring of patients treated with imatinib is mandatory.
UR - http://www.scopus.com/inward/record.url?scp=30444452088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30444452088&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-05-1816
DO - 10.1182/blood-2005-05-1816
M3 - Article
C2 - 16195326
AN - SCOPUS:30444452088
SN - 0006-4971
VL - 107
SP - 480
EP - 482
JO - Blood
JF - Blood
IS - 2
ER -